Monday , May 23 2022
Home / Tag Archives: bioverativ

Tag Archives: bioverativ

Sanofi Acquiring Synthorx for $2.5B to Strengthen Immuno-Oncology Portfolio

French multinational company Sanofi SA stated on Monday that it will buy biotechnology company Synthorx Inc. for a combined equity value of approximately $2.5 billion. In other words, it will be $65 per share.The acquisition is expected to close in the first quarter in 2020 and the company believes it will strengthen Sanofi’s existing immuno-oncology portfolio.Paul Hudson, who is the CEO of Sanofi, said:“This acquisition fits perfectly with our strategy to build a portfolio of high-quality...

Read More »